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ABSTRACT
There have been great scientific and technical advances in 
biomedicine in the last few years, particularly after the de-
scription of the human genome. These improvements have 
gradually been applied in diverse fields that have gone be-
yond the study of the disease to enter the study of health. 
The latter includes research in the field of physical and 
sports activity. Genetics therefore provides the scientific 
knowledge that helps us to optimise the performance of 
high level sportsmen/women, to reap the benefits of carry-
ing out physical exercise and/or to perform a safe sports 
practice by evaluating the risk of a hereditary disease as-
sociated to sudden death in sportsmen/women.
KEY WORDS: Genetics. Sport. Physical condition. Sudden 
death. Arrhythmic syndromes.
RESUMEN
La biomedicina ha experimentado grandes avances científi-
cos y técnicos en los últimos años, especialmente después 
de la descripción del genoma humano. Estas mejoras se han 
aplicado gradualmente en diversos ámbitos, que han sobre-
pasado el estudio de la patología para adentrarse en el es-
tudio de la salud. En esta última se incluyen investigaciones 
en el campo de la actividad física y el deporte. La genética, 
por tanto, aporta unos conocimientos científicos que pue-
den ayudarnos a optimizar el rendimiento de un deportista 
de alto nivel, rentabilizar los efectos de la práctica del ejer-
cicio físico y/o llevar a cabo una práctica deportiva segura, 
evaluando el riesgo de una enfermedad hereditaria asociada 
a la muerte súbita en deportistas.
PAlABRAS ClAVE: Genética. Deporte. Condición físi-
ca. Muerte súbita. Síndromes arrítmicos..
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IntroductIon
The importance of adhering to an active healthy lifestyle is 
well documented. In adults, research has shown the importance 
of physical activity for the prevention of cardiovascular disease, 
metabolic syndrome, type 2 diabetes, and obesity as well as 
promoting longevity1-4. In children and adolescents, a recent 
review indicates that taking part in some physical activity is 
associated with a series of positive effects on health5.
To the extent that sporting activities have been made 
official, whether through participation in regulated activities or 
with more competitions, a larger group has made the leap from 
purely recreational to amateur competition, where the athletes 
themselves look for continuous improvement in their ability to 
play a sport. So it is not strange to suggest that those who 
participate in sports are looking to improve their performance 
through more rigorous training and better nutrition. The 
progress made in molecular level understanding of physical 
capacity, including genetic factors, generates more interest in 
the technology in order to predict anything from the best type 
of exercise, to the risk of suffering a muscle injury.
Within the context of genetic advancement in sports, the 
information with reference to sudden death in sports 
practitioners caused by hereditary genetic diseases stands out. 
Even though very infrequent, the sudden death of an athlete 
has an instantaneous impact through the media, creating 
significant social alarm.
The sciences of physical activity and sports are an area of 
research that can’t escape the changes being experience in 
molecular biology, and specifically in the field of human 
genetics and genomics. As such, whether the purpose is to 
study the impact of a training program targeting performance, 
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to analyse the effects of physical activity, or to evaluate the risk 
of suffering from a hereditary disease associated with sudden 
death in sports practitioners, human genome information has 
become an important element for different research projects. 
genetIcs
Many important historical events have taken place in order 
to prepare the human genetic map. From publication of Charles 
Darwin’s Origin of the Species (1859), to Gregor Mendel’s pea 
experiments (1865), the launch of the Human Genome Project 
(1990), the preparation of a detailed map of human genetics 
(1995) and finishing the human genome sequence (2003), in 
the last 25 years the study of molecular biology has experienced 
a significant revolution and currently its influence is highly 
relevant in the science fields6.
All living organisms have their own genetic information 
contained in the DNA molecule (deoxyribonucleic acid). In it 
are found the units of heredity, genes. We humans have 30,000 
genes distributed in 23 pairs of chromosomes located in the 
nucleus of our cells (22 autosomal pairs and 1 pair of sex 
chromosomes) and a single mitochondrial chromosome. Each 
pair of chromosomes (counterparts) has the same genes – of 
which we have two copies called alleles. Each gene contains the 
necessary information for protein synthesis; it is an organism’s 
functional unit, given that the organism’s smooth operation is 
based on the perfect synthesis of all necessary proteins.
The DNA molecule is made up of 4 different types of 
nucleotides repeated millions of times. The majority of DNA 
do not encode proteins and those fragments that do are called 
genes. In the encoder portion of the gene, each group of three 
nucleotides is encoded for a specific amino acid. This is a 
chained process; the three first nucleotides encode the first 
amino acid, the three following the second, and so on. The 
order followed by the nucleotide sequence in the DNA 
determines this synthesis. The progressive accumulation of all 
of the gene’s amino acids leads to the creation of protein. In the 
human genome at least 1.5% of these are described as containing 
sequences that encode proteins7. The rest of the material may 
help proper functioning, but its purpose has not yet been 
clearly established. 
On occasion insertion, deletion, or change in the order of 
the nucleotides may occur. They are genetic defects called 
mutations; they can produce the synthesis of a different or 
defective protein causing disease. Whether an individual 
develops a disease caused by mutation or not, depends on the 
importance of the particular protein to the overall functioning 
of the human body. If the mutation affects the DNA of a 
germinal or reproductive cell, it will be transmitted to 
subsequent generations causing hereditary disease.
Hereditary diseases are classified as:
1. Chromosomal alterations, with the deletion or addition 
of a part of or an entire chromosome.
2. Polygenic diseases (the most frequent), where the disease 
is due to the interaction of different genes.
3. Monogenic diseases. Just one gene is primarily responsible 
for this disease, and its hereditary pattern follows the laws of 
Mendel which are:
–  Autosomal dominant diseases. One of the hereditary alleles 
is defective and the other is normal. The dominant nature of 
the disease means that with just one allele affected by a 
mutation it can cause disease. Descendents have a 50% 
chance of being carriers of the disease if one of the parents is 
affected. Each generation is affected and men as well as 
women can inherit and transmit the disease.
–  Autosomal recessive diseases. Both alleles must be defective 
for the disease to occur. As such, it is a less common form 
than autosomal dominant disease. If both parents are carriers, 
their descendents have a 25% chance of suffering from the 
disease and a 50% chance of being carriers.
–  Diseases linked to sex. Women provide one of the X 
chromosomes. Men, having only one X chromosome, suffer 
from the disease if they inherit the mutated chromosome.
–  Mitochondrial diseases. Always transmitted by females, 
because the mitochondrial chromosome always pertains to 
the mother. As such there is no male to male transmission.
In general, all human beings show small variations called 
polymorphisms in some part of their DNA. Unlike mutations, 
polymorphisms in general, do not cause diseases but can alter 
the response of an individual to them, producing variations in 
predisposition, development, and response to treatment8,9.
BasIc concepts: genetIcs, genomIcs, genotype, and 
phenotype
The evolution experienced by molecular biology has led to, 
among other things, more common and sometimes 
indiscriminate use of a particular vocabulary. Due to that 
situation, we thought it best to conceptualize some of those 
terms and create a framework for the subject we are dealing 
with in this article.
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First of all we should differentiate genetics from genomics. 
Genetics is understood to be the biological sciences that 
attempt to understand how biological heredity is transmitted 
from one generation to the next and how those processes 
develop. A goal of genetics is to study heredity patterns and 
how they are transmitted from parents to children. On the 
other hand, genomics includes a set of sciences and techniques 
dedicated to the integrated study of the function, evolution, 
and origin of the genomes6,10. Even though genetics and 
genomics are conceptually different, they share some basic 
areas of study such as genes and DNA.
Genotype and phenotype are two more basic concepts that 
should be kept in mind to help understand issues arising from 
the research in this area. Genotype refers to all of an individual’s 
genetic material. The visible features of an individual are called 
phenotype6,10. For example, in the case of diseases, if an 
individual is genetically predisposed to suffer from cardiovascular 
diseases such as Brugada Syndrome, we are talking about 
genotype. If this disease manifests on its own and develops, we 
are talking about phenotype.
a questIon of desIgn
In Origin of the Species Charles Darwin shows that all 
organisms must work to survive and that only the vigorous, 
healthy, and happy are capable of multiplying. In fact, we 
could say that exercise has been programmed in our genes since 
the Palaeolithic era. The environmental factors that our 
ancestors had to face, where fitness was an important factor in 
survival, caused our genes to evolve in relation to the 
environment in which they lived11,12.
The environmental factors of well-off societies are very 
different from those of the Palaeolithic era; so we find ourselves 
with an evolutionary design incompatible with our current 
environmental conditions. This fact induces many of the 
diseases our society suffers from today11. 
Between genotype and phenotype, environmental factors 
(food, physical activity, hygiene habits, etc.) play a very 
important role. Whether individually or collectively, these 
factors can interact with the genotype and be precursors to the 
manifestation of phenotypes (fig. 1).
fItness genotypes and phenotypes
To discuss fitness and genetics, first we need to decide what 
we mean by fitness and what its characteristics are. The concept 
of fitness may have different interpretations depending on the 
area we are dealing with. In keeping with the subject of this 
article, we would like to identify what health related fitness and 
the kind of fitness related with sports performance are. 
In the health field, fitness can be seen as the degree of 
energy and vitality a person needs to be able to perform 
common daily tasks: actively enjoy free time, handle unforeseen 
emergencies without excessive fatigue, prevent certain diseases 
deriving from sedentariness, and facilitate maximum 
development of intellectual capacity, thoroughly enjoying life. 
From the sports perspective, fitness is a performance component 
and the maximum optimization of the components of fitness 
is a goal13-16. 
For the purposes of establishing a criterion to help us 
understand some of the aspects of this article, and without 
getting into a conceptual debate or nuances, we consider 
fitness to be made up of physical capacities. We can classify 
these capacities in motor or basic capacities (strength, aerobic/
anaerobic endurance, and speed), coordinating and perceptive-
motor capacities (general/specific coordination and balance), 
the resulting capacities (agility), and the facilitating capacities 
(flexibility-elasticity, muscle/joint mobility)14. Beyond this 
classification, we would agree that conditional capacities are 
based mainly in energetic and coordination processes 
preferably in regulation and conduction of the central nervous 
system53.
Whether from the perspective of sports or physical exercise, 
all of these fitness elements can be measured in one way or 
another. From VO2max. (ml·Kg–1·min–1 o l/min), time (sec.), 
speed (m/s) and strength (kg.), etc. As an example, a person 
Figure 1 Genotype-phenotype relationship.
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can have a genetic substrata (genotype) related to cardiovascular 
endurance that could manifest itself as values of VO2max 
(phenotype) that are measurable and modifiable by different 
environmental conditions such as training loads, food, etc.
Nevertheless, we shouldn’t have a Mendelian view of the 
individual in regards to fitness phenotypes as there are many 
factors that interact: social, physiological, metabolic, cellular, 
and molecular. In addition, the effect of genetic material on 
fitness phenotypes is also determined by susceptible genes that 
can predispose a phenotype, and by the interaction among 
different genes, questions that are still being studied. Because 
of this, fitness phenotypes are called complex phenotypes as 
they occur with complex disease phenotypes (fig. 2).
The human gene map for fitness
After completion of the human genome sequence, research 
has been done and continues being done to determine the 
genes implicated in different fitness phenotypes. Preparation of 
this genetic map relies on the contribution of various research 
projects done year after year. However, the interpretation of the 
results of these studies must be understood within the context 
of the strategy used for the research.
Research strategies
In human studies, research methods are based on genetic 
epidemiology, and more recently on molecular studies. Broadly, 
genetic studies can be classified in two large groups. First, there 
are those based on genetic epidemiology, focusing on family 
and individual phenotypes. Second, there are those more 
related to molecular biology that attempt to measure DNA 
variation based on candidate gene markers.
To analyze the genetic base of complex phenotypes, such as 
physical capacity, there are three major methods17-20. First, 
there are heritability studies that attempt to evaluate genetic 
and environmental contributions to the phenotypes of members 
of the same family, twins, or individuals adopted by families. 
For example, some estimate that the degree of heritability of 
the VO2max is approximately 50%, as related to muscle fibre 
type between 40% and 50%, and for muscle strength 70%.
The second major method uses Genome-wide linkage scans, 
consisting of a genetic examination of markers found in the 
entire human genome in a very large group of individuals 
enabling subsequent associations between each marker and 
specific phenotypes. There is an attempt to locate human 
genome regions that have a high probability of being related to 
the consumption of oxygen, % of body fat, or the regulation of 
heart rate. 
The third major strategy, and one of the most used, is the 
study of candidate-gene association. It involves looking for a 
candidate gene believed to influence the regulation of one of 
the fitness phenotypes. From there, the most common variations 
of this gene (allele) are studied in a large number of subjects. 
At this point two types of research may be encountered. The 
first studies a single variation of the gene (allele) of a specific 
subject, and in the other they study control cases to try and see 
if a gene or its variation is more common in elite athletes than 
in the normal population. These two research options are those 
that were used to identify a number of fitness associated genes, 
whether in the general population or in elite athletes.
Genes and fitness
The genes added to the fitness genome are published 
annually in the The Human Gene Map for Performance and 
Health-Related Fitness Phenotypes. Although the studies relating 
to fitness phenotypes are varied, we present some examples. In 
case control studies related to endurance sports we find genes 
like AMPD1, PPARGC1A and ACE, and with speed tests we 
have ACTN3. In the case of association studies with candidate 
genes we find phenotypes studied like VO2max associated with 
Interaction 
gene-gene
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training
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Necessary
genes
Susceptible
genes
Interaction
gene-
environment
Figure 2 Interaction of the different elements in the 
physical condition.
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genes like ADRB2, HLAA, CFTR and HIF1A, the post-
exercise lactate associated with genes like ACE, or strength 
associated with DI01 and IGF220 (table I).
Possibly the gene variants, as well as being associated with 
sports performance, are found in people that exercise to benefit 
their health. In general, these variants studied in elite athletes 
are very common in the population. Those genes related to 
energy metabolism, cardiorespiratory response to maximum 
exercise, etc., are important factors for the general population 
as well as the athlete. Although the study of the genetic 
characteristics of high level athletes contributes valuable 
information regarding the benefits of physical exercise for the 
general population, we must note that not all variants we find 
in first rate athletes should be seen as a health reference in the 
fitness world. This is the case with those genetic variants that a 
long distance runner might have that enable him to conserve 
energy during long periods of intense physical activity, given 
that this would not be valuable in little active or sedentary 
individuals.
genetIcs and sudden death In athletes
Sudden cardiac death is defined as death from cardiac 
causes occurring in the first hour after the first symptoms. 
Sudden death is found in 1/1000 in the general population, 
but increases significantly if there is a more serious cardiac 
pathology. Sudden death in athletes is not frequent21,22 even 
though the real incidence may be larger than thought due to 
the fact that certain conditions like ion channelopathies, which 
predispose to lethal arrhythmias, are not associated with 
structural heart disease, and therefore the cause of death 
remaining unclear. Approximately 80% of non-traumatic 
sudden death in young athletes is caused by hereditary 
cardiovascular anomalies; as such, they have a repercussion on 
families23-25. The majority (>80%) of sudden cardiac deaths 
(SCD) in young athletes occur during or immediately after 
excercise26. This suggests that exercise may be a cardiac 
arrhythmia trigger in those individuals with certain cardiac 
disorders.
Most SCD in athletes occurs in young men (12-40 years 
old). Often SCD is the first symptom of the disease. SCD is 
usually directly related to exercise and at autopsy, it could be 
completely normal (suspicion of arrhythmogenic disease) or 
abnormal with the detection of structural cardiac alterations24,26-28. 
Among structural diseases, the most written about are 
hypertrophic cardiomyopathy (HCM), causing 40% to 50% 
of the cases, and arrhythmogenic right ventricular dysplasia 
(ARVD), the most frequent cause of SCD in athletes in certain 
areas of Italy. 
There are multiple genetically determined cardiac 
pathologies, with or without accompanying structural 
cardiopathy, that may predispose to the appearance of 
arrhythmias and sudden death29-31. These diseases are the 
product of alterations in the genetic encoding of four large 
families of proteins:
•  Sarcomeric proteins, which generate strength in the cardiac 
myocyte and are responsible for hypertrophic 
cardiomyopathy32.
•  Cytoskeletal proteins, which transmit the strength to the 
adjacent cells that cause dilated cardiomyopathy33. 
Table I Most important gens associated with sports.  
Objective Gen
Endurance PPARD
 Nuclear respiratory factors (NRF2)
 PGC-1alpha
 HIF-1alpha
 EPAS-1and HIF-2alpha
 Haemoglobin
 Skeletal muscle glycogen synthase (GYS1)
 ADRB2
 CHRM2
 VEGF
Muscular CK-MM
 ACTN3
 MLCK
 ACE
 AMPD1
 IGF-1
Tendon ABO blood group
 COL1A 1 and COLSA 1
 TNC
Psychology Serotonin transporter gene (SHTT)
 BDNF
 UCP2
Adapted from Lippi, 20099.
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•  Proteins that encode ion channels, responsible for maintaining 
the intra and extracellular ion balance, as well as responsible 
for familiar arrhythmias34.
•  Desmosomal proteins enable structure maintenance and 
intercellular communication.
But there is a significant overlap between genes and 
diseases35; for example troponin T can cause dilated 
cardiomyopathy as well as hypertrophic cardiomyopathy36,37; 
the sodium channel SCN5A is one of the genes responsible for 
the Brugada Syndrome, long QT syndrome type 3 (LQTS3), 
and also familial conduction alterations38,39.
dIseases
Brugada Syndrome
Brugada Syndrome (BrS) has a characteristic ST segment 
elevation that is easily identifiable in the cases with a “classic 
pattern”. Unfortunately, non-specific or incomplete changes of 
the ST segment, or right bundle branch block are common in 
the general population. If there is a suspicion that the disease 
is present, then in these less classic cases it is advisable to 
perform an ajmaline test, in which the intravenous 
administration of the sodium inhibitor can unmask the 
diagnostic electrocardiographic pattern.
It is thought that the physiopathological mechanism 
responsible for ST elevation and susceptibility to ventricular 
arrhythmias is an imbalance between input and output of ion 
currents during phase 0 and 1 of the action potential. Until 
now, only two genes were associated to the disease (SCN5A, 
sodium channel encoding, and GPD1L, glycerol-3-phosphate 
deshydrogenase-1). Curiously there is no information with 
respect to sudden death in athletes caused by Brugada Syndrome, 
but given that the ecg pattern can become worse during febrile 
episodes, clinical practices have begun advising those affected 
by the disease not to participate in sports due to the increase in 
body temperature, a fairly controversial decision (Table 2).
Catecholaminergic polymorphic ventricular 
tachycardia 
Catecholaminergic polymorphic ventricular tachycardia 
(CPVT) is a familial disease that causes exercise and/or stress 
induced SCD. CPVT is a disorder of intracardiac calcium 
aggravated by sympathetic stimulation. Mutations of the 
ryanodine receptor (Ryr2), calsequestrin 2 CASQ2), and 
ankyrin-2 (ANK2)) produce calcium overload that has been 
linked with the disease. (Table 2).
long QT Syndrome
Long QT Syndrome is characterized by prolongation of the 
QT interval in a resting ECG (> 470 ms for men and > 480 ms 
for women as a diagnostic, and 440-470 as a limit). The 
syndrome was initially related to loss of function in the 
potassium channels and increased function in the sodium 
channel. In all cases, the consequence is a prolonged action 
potential that facilitates depolarization, a substratum of 
ventricular arrhythmias (table II).
Clinically, up to 30% of LQTS cases have a QT interval at 
the limits of normal that require additional studies (phenotype, 
genetic, or both) in order to reach a diagnosis. Given the variety 
of mechanisms that drive the LQTS, identification of the 
causal mutations is crucial for orienting therapy. Nevertheless, 
the results of genetic analysis are negative in a third of patients, 
accentuating the need to improve phenotypic detection. 
Short QT Syndrome
Short QT Syndrome (SQTS) is characterized by the 
presence of shortening of the QT in ECGs (<340 ms suspect 
and <320 clear diagnostic) and clinically by the presence of 
syncopal episodes, paroxysmal atrial fibrillation, and/or lethal 
arrhythmias. Even though the cases of some affected families 
have been published, there is little information about the 
disease. SQTS has been linked to mutations in genes that 
encode potassium channels. Three genes have been identified 
up to now; this fact demonstrates that the disease is genetically 
heterogeneous. Even though clinical studies and physiopathology 
have suggested quinidine as the appropriate treatment for 
STQS-1, the high incidence of SCD justifies implant of a 
defibrillator in the majority of cases (table II).
Arrhythmogenic right ventricular dysplasia
Arrhythmogenic right ventricular dysplasia (ARVD) is a 
familial cardiac muscle disease40 characterized by structural 
changes (progressive right ventricular replacement of the 
myocardium by fibroadipose tissue), and clinically characterized 
by ventricular arrhythmias, with a high risk of cardiac arrest41,42.
Even though the disease43 has been studied for 25 years, 
certain forms of ARVD are not easy to diagnose. Early diagnosis 
of the disease is difficult because there is no clear pattern of how 
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the tissue is affected. MRI is a useful tool for diagnosis, but 
interpretation is difficult in some cases. Also, in some patients 
malignant ventricular arrhythmia may be the first sign of ARVD. 
Genetic tests help in clinical diagnosis because we can now 
diagnose nearly 60% of cases thanks to genetic studies targeting 
the analysis of desmosomal protein mutations (Table 3).
Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is a disease of the 
myocardium characterized by left ventricular asymmetric 
hypertrophy, with findings of disarray of the myocytes and 
fibrosis44,45. It is the most frequent cardiovascular genetic 
Table II Ionic diseases of genetic origin
Channel Disease Heretability locus Gen
Sodium Long QT 3 Autosomal dominant 3p21-23 SCN5A
 long QT 10 Autosomal dominant 11q23 SCN4B
 Brugada Syndrome (SBr) Autosomal dominant 3p21 SCN5A
  Autosomal dominant 3p24 GPD1-L
 Lev-Lenègre Syndrome Autosomal dominant 19q13.2 ?
  Autosomal dominant 3p21 SCN5A
 Atrial fibrilation (AF) Autosomal dominant 3p21 SCN5A
Sodium relation Long QT 9 Autosomal dominant 3p25 Cav3
Potassium Long QT 1 Autosomal dominant 11p15.5 KCNQ1
 Long QT 2 Autosomal dominant 7q35 KCNH2
 Long QT 5 Autosomal dominant 21p22.1-22-2 Mink(KCNE1)
 Long QT 6 Autosomal dominant 21p22.1-22-2 MiRP1(KCNE2)
 Long QT 7 Autosomal dominant 17p23.1-24.2 KCNJ2
 Long QT 1 Autosomal recessive 11p15 KCNQ1
 Long QT 5 Autosomal recessive 21q22 Mink
 Short QT 1 Autosomal dominant 7q35 HERG(KCNH2)
 Short QT 2 Autosomal dominant 11p17 KCNQ1
 Short QT 3 Autosomal dominant 17q23 KCNJ2
 Atrial fibrilation Autosomal dominant 10q22 ?
  Autosomal dominant 11p15.5 KCNQ1
  Autosomal dominant 11q23 KCNA5
  Autosomal dominant 12p13 KCNE3
  Autosomal dominant 21q22 KCNE2
  Autosomal dominant 17q23 KCNJ2
Calcium SBr and short QT 4 Autosomal dominant 12p13.3 CACNA1C
 SBr and short QT 5 Autosomal dominant 10p12.33 CACNB2b
 Timothy Syndrome (QTL8) Autosomal dominant 12p13.3 CACNA1C
 Polymorphic ventricular tachycardia (TVP) Autosomal dominant 1q42 RYR2
  Autosomal recessive 1p13 CASQ2
Calcium relation Long QT 4 Autosomal dominant 4q25-27 ANKB (ANK2)
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alteration, with an incidence of 1 in 500 in the general 
population, especially effecting young people46-48. Clinical 
manifestations appear initially as diastolic dysfunction and as 
systolic in more advanced cases, meaning the patient can be 
asymptomatic or suffer cardiac failure or sudden death. The 
rate of death is greater in young patients (frequently athletes) 
than in adults and the first signs of the disease can be specifically 
sudden death. The disease is considered familial in 90% of 
cases, generally with an autosomal dominant hereditary 
pattern, the exception being cases with mitochondrial DNA 
mutations (mtDNA), which are inherited from the mother. 
More than 400 mutations49-50 (table IV) have been 
identified.
Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is characterized by 
ventricular dilation that alters systolic function, mainly in the 
left ventricle. Patients present signs of cardiac failure, 
palpitations, or sudden death. The prevalence is 1 in 2,500 
people. There are multiple factors that that can trigger dilated 
cardiomyopathy, making it a highly heterogeneous entity. 
Nevertheless, systematic studies of the families of patients with 
dilated cardiomyopathy indicate that at least 35% of the cases 
are hereditary51. The arrhythmias shown by patients with 
familial dilated cardiomyopathy are usually the same as in the 
acquired forms with atrioventricular and intra-ventricular 
conduction, ventricular arrhythmias, and atrial fibrillation. 
These patients normally develop progressive deterioration of 
the ventricular function and die of cardiac failure or 
arrhythmias. 
In 1994 the first DCM locus with atrioventricular block in 
chromosome 1 was found52. The scenario of this disease is 
extremely complex given that the usefulness of genetic clinical 
analysis is limited. Twenty mutations have been found in genes 
that encode cytoskeleton, cell nucleus, and sarcomere proteins. 
Some of the most significant mutations (30%) are found in the 
lamin A/C gene (LMNA)53 that encodes a protein found in 
almost all types of cells and whose function is to provide 
nucleus integrity with mechanical support54. Other genes such 
as MYH7 and TNNT2, previously identified as causes of 
hypertrophic cardiomyopathy, can also cause dilated 
cardiomyopathy. In addition, SCN5A, a gene that was thought 
to only cause electrical disease55 (Chart 5) was identified in a 
family with SCD mutation.
genetIc dIsease sports recommendatIons
In 1994 the 26th Bethesda conference for formulating 
guidelines for participation in competitive athletic sports with 
Table III Genes involved in arrythmogenic right 
ventricular dysplasia (ARVD)
Disease locus Gen
ARVD 1 14q23-24 TGFβ3
ARVD 2 1q42-q43 RyR2
ARVD 3 14q12-q22 ?
ARVD 4 2q32.1-q32.3 ?
ARVD 5 3q21.3-3p23 LAMR-1
ARVD 6 10p12-p14 ?
ARVD 7 2q35 Desmin
ARVD 7 10q22.3 ZASP
ARVD 8 6p24 Desmoplaquin (DSP)
ARVD 9 12p11 Placofilin-2 (PKP2)
ARVD 10 18q12.1-q12.2 Desmoglein-2 (DSG2)
ARVD 11 18q12.2 Desmocollin-2 (DSC2)
Naxos 17q21 Placoglobin (JUP)
Table IV Genes involved in hypertrophic cardiomyopathy
locus Gen
14q12 MYH6
14q12 MYH7
11p11.2 MYBPC3
12q24.3 MYL2
3p21 MYL3
1q32 TNNT2
19q13.4 TNNI3
15q22.1 TPM1
15q14 ACTC
2q24.3 TTN
3p TNNC1
11p15.1 CRP3
17q12 TCAP
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an identified cardiovascular alteration56 was organized. Experts 
in cardiovascular sports medicine and sports cardiology drew 
up recommendations by consensus, providing a base for the 
medical assessment of patients. The guidelines depend on the 
nature and seriousness of the cardiovascular anomalies and the 
classification of the sport in question.
In nearly a third of SCDs, the autopsy reveals no structural 
or morphologic anomaly. It is possible that in these cases the 
origin of death could be purely electric and in the cases of 
familial disease, a channelopathy. Known entities such as 
polymorphic ventricular tachycardia, idiopathic ventricular 
fibrillation, short and long QT syndromes, and Brugada 
Syndrome are entities included under this epigraph of 
channelopathies. 
Sudden death in young athletes always has an important 
repercussion in the media. Owing to the superhuman efforts 
that they make, there are some clear criteria regarding 
participation in competitive sports56-60.
Athletes with a clear diagnosis of HCM, ARVD or DCM, 
should not participate in most competitive sports, with the 
possible exception of less intense sports (for example, bowling, 
golf, or curling). This is independent of the presence of 
symptoms and the magnitude of the hypertrophy of the left 
ventricle (HLV), or the obstruction of the exit tract in the case 
of HCM.
It is recommended not to practice competitive sports in 
the case of genetic arrhythmia diseases, especially due to the 
implications that the adrenergic surge could trigger 
arrhythmia. Recommendations in the case of Brugada 
Syndrome are less clear, but due to the association of the 
disease with fever, it is considered necessary to advice against 
participating in sports due to the increase in body temperature 
during sport.
evaluatIon of athletes wIth characterIstIcs of 
possIBle cardIac dIsease
Cardiovascular evaluation in young athletes targets the 
identification of conditions that could be a risk of sudden 
death for the athlete. Ideally, all athletes should, at a minimum, 
be evaluated in order to diagnose possible cardiovascular 
alterations before any athletic participation. But people who 
participate regularly in sports should have a basic clinical 
evaluation (physical examination and clinical history) and a 
resting electrocardiogram.
After basic clinical examinations of the athletes, it is 
important to give priority to deeper studies of those athletes 
that present a greater risk of having hereditary cardiac anomalies. 
These are of course symptomatic athletes, and those that have 
a family history of familial disease associated with sudden 
death.
Among the studies to be carried out, currently a genetic 
study can be considered. Genetic studies are effective in cases 
of known hereditary disease, but not so much if the cause of 
sudden death or the symptoms are still not known. In the latter 
case, the quantity of genes that must be analyzed is so great 
that it is not economically feasible. In the next months it will 
be possible to analyze these cases rapidly, thanks to the 
technological development of diagnostic chips targeting 
arrhythmic diseases.. This chip enables analysis of more than 
20 genes in a reduced amount of time, improving service and 
especially cost. 
conclusIons
Throughout history, society has found a special place for 
the few who are faster, stronger, and physically gifted. There 
are several studies that indicate that genes may play an 
important role in the fitness of elite athletes, although it is 
early to try to identify if a single gene or group of genes can 
Table V Genes involved in dilated cardiomyopathy
locus Gen
14q12 MYH7
15q14 ACTC
1q32 TNNT2
15q22.1 TPM1
2q24.3 TTN
11p15.1 CRP3
17q12 TCAP
Xp21 Distrofin
2q35 Desmin
10q22.1-10q23 Metavinculin
4q12 β-sarcoglican
5q33 δ-sarcoglican
Xq28 Tafacin
1q21 Lamin A/C
6q22.1 Fosfolamban
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determine the sports potential of an individual. Genetics can 
also determine the risk of sudden death in an athlete. When 
SCD happens to an athlete, it is tragic news with significant 
social impact. 
As such, it is clear that in the coming decades a field of 
research is opening where we must include, and adapt to, 
genomic technology and bioinformatics with a goal of 
understanding the influence of genetics on the fitness of 
individuals and their risk for disease.
Table VI Differences between 26.a Bethesda and ESC
 Clinical criteria and permited sports
 ACC ESC
Carriers without genetic phenotype  All sports Only recreational sports 
 (HCM, DCM, ARVD)
LQTS > 0,47 men > 0,44 men
 > 0,48 women > 0,46 women
 Low intensity competition sports Recreational
Non-sustained ventricular tachycardia Without CV disease, all competitive sports.  Without CV disease, all sports. With CV disease,  
  With CV disease, low intensity   only recreational sports 
  competition sports  
ACC: American College of Cardiology; HCM: hipertrophic cardiomyopathy; DCM: dilated cardiomyopathy; ARVD: arrythmogenic right ventricular dysplasia; ESC: European Society 
of Cardiology; LQTS: long QT syndrome.
Adapted from Pelliccia, 2008.
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